PRODUCT NEWS DIGITAL IMMUNOASSAY SYSTEM
To receive prompt and free information on products, log on to www.LinkXpress.com or fill out reader service form located on last page
DATA MANAGER
RAPID IMMUNOASSAY TEST
BD Diagnostic Systems
Instrumentation Lab
Luminex
The BD Veritor Plus is designed for the detection of influenza A&B, RSV and group A strep, with enhanced documentation functionality. It provides accurate test results within minutes and is suitable for healthcare providers and clinical lab professionals.
The HemoHub allows users to view critical results and analyzer status in RT, set up automatic reruns and reflexes, and minimize interruptions. It standardizes testing across systems/networks by allowing users to monitor QC and provide better patient care from a single workstation.
The ARIES Flu A/B & RSV assay is for the detection/differentiation of influenza A&B, and RSV from nasopharyngeal swabs. It features integrated sample processing control to ensure the assay run is successful from extraction through amplification with results delivered in less than two hours.
LINKXPRESS COM
LMI-17-04 207
LINKXPRESS COM
LMI-17-04 208
LINKXPRESS COM
LMI-17-04 209
Rapid New Test Detects Chlamydia Infection novel system DNA probes with bespoke electrochemical tags attached to accurately detect for infectious diseases and this system has significant benefits over existing diagnostic tests, allowing for faster results. The World Health Organization (WHO; Geneva, Switzerland; www. who.int) has estimated that 499 million new sexually transmitted infections (STIs) occur each year and this novel diagnostic tool could soon be helping to win the fight against the spread of these diseases. Atlas Genetics Ltd. (Bath, UK; www.atlas genetics.com), the ultra-rapid Point-of-Care (POC) molecular diagnostics company, has announced that it has received approval to CE marking its Chlamydia trachomatis (CT) test to be launched on the Company’s io platform. By meeting the requirements of the in vitro Diagnostics (IVD) Directive (98/79/EC), the CT test is now cleared for sale within the European Union. The evaluations conducted on the io CT test
A
demonstrated that performance is equivalent to the gold standard laboratory test and will not be compromised by the transition of testing away from the central laboratory to the point-of-care (POC) setting, or by the level of experience of the operator performing the test. This is the first molecular POC test for a Sexually Transmitted Infection (STI) to enter the market, capable of delivering test results in just 30 minutes. With the speed and accuracy of the io CT product, the testing and treatment of patients within a single, brief visit to the clinic now becomes a reality. The Chlamydia test is the first in a pipeline of tests to be launched on the io platform. Further menu development will include tests for Gonorrhea, Trichomonas vaginalis and other STIs, for both the European and US markets. While Atlas’ commercialization strategy is initially focused on the area of sexual health, the io platform technology can be applied in a wide range of infectious disease and oncology diagnostic test areas.
Image: The io system is a highly novel molecular diagnostic system for the ultra-rapid diagnosis of a broad range of infectious diseases including sexually transmitted infections (Photo courtesy of Atlas Genetics).
Aberrant Gene Expression Predicts Metastatic Endometrial and Lung Cancers he spread of cancer cells from the initial site of occurrence, the primary site, to other secondary tissues is called metastasis, and contributes to poor or limited response of cancer cells to treatments, which results in death. For example, cancer cells initially in the lungs can begin to spread to other organs, including the brain and liver. Gynecologic cancer typically originates from the female reproductive organs, and includes endometrial and ovarian cancer, among others. Survival rates are typically very poor for these cancer-types, with limited response to existing therapies and a major reason for poor survival rates is late diagnoses, by which time the cancer cells have spread to secondary sites. Scientists from Georgia State University (Atlanta, GA, USA; www.gsu.edu) and the University of Oklahoma College of Medicine (Oklahoma City, OK, USA; www.ouhsc.edu) obtained more than a hundred clinical endometrial cancer specimens and matching serum. Using multiplex arrays and a variety of exper-
T
imental approaches, they analyzed the specimens for gene targets that positively or negatively correlated with metastatic potential of the tumors. Data were translated to reflect the patient’s age at diagnosis, disease stage, grade and histology. Serum specimens were evaluated for levels of cpeptide, interleukin-6 (IL-6,) insulin, leptin, monocyte chemoattractant protein-1 (MCP-1 or CCL2) and tumor necrosis factor alpha (TNFα) using a custommade multiplex kit subset of the MILLIPLEX MAP Human Metabolic Hormone Magnetic Bead Panel (EMD Millipore; Billerica, MA, USA; www.emd millipore.com), for levels of adipsin and adiponectin, using the Bio-Plex Pro Human Diabetes Adipsin and Adiponectin Assay (BIO-RAD Laboratories Inc., Hercules, CA, USA; www.bio-rad.com) and for levels of angiopoietin-2, follistatin, G-CSF, HGF, IL-8, leptin, PDGF-BB, PECAM-1 and VEGF, they used the BioRad Bio-Plex Pro diabetes kit. The scientists found that enhanced neuropilin-1 (NRP-1) expression significantly correlated with in-
creased tumoral expression of vascular endothelial growth factor 2 (VEGFR2) and serum levels of hepatocyte growth factor (HGF) and cell growth-stimulating factor (C-GSF). Tumoral NRP-1 also was positively associated with expression of neural precursor cell expressed developmentally down-regulated protein 9 (NEDD9), a pro-metastatic protein. In the highly metastatic lung cancer cell line (H1792), stable LKB1 depletion caused increased migration in vitro and accentuated NRP-1 and NEDD9 expression in vivo. Imoh S. Okon, PhD, a professor and lead author of the study said, “In this study, we found that enhanced neuropilin-1 (NRP-1) and NEDD9 levels in endometrial and lung cancer positively correlated with metastasis, while liver kinase B1 (LKB1) inhibited the migration of cancer cells. Our study provides strong translational potential with respect to biomarkers that play critical roles in the development of endometrial/ lung tumors.” The study was published on December 20, 2015, in the journal Oncotarget. LabMedica International April/2017
18